Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20107353 | 0.96 | LMNA (0.61) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL24920331 | 0.89 | LMNA (0.49) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL29467724 | 0.87 | LMNA (0.56) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL14768516 | 0.86 | LMNA (0.61) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL20526175 | 0.86 | SMN1; SMN2 (0.69) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL26689707 | 0.86 | LMNA (0.61) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL4513964 | 0.86 | SMN1; SMN2 (0.69) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL26689306 | 0.86 | LMNA (0.61) | LMNASMN1; SMN2IDO1SYKBCHE | |
| SCHEMBL25030511 | 0.86 | LMNA (0.59) | LMNASMN1; SMN2IDO1SYKGBA1 | |
| SCHEMBL25029156 | 0.86 | LMNA (0.59) | LMNASMN1; SMN2IDO1SYKGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20210206822-A1 | Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| US-10968264-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICS NV (BE) | 2021-03-30 | — | — | US | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-10 | — | — | US | disclosed |
| WO-2018081367-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LMNA 385/4885SMN1; SMN2 3778/4885IDO1 3089/4885 |
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
| US-20210206822-A1 | Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LMNA 385/4885SMN1; SMN2 3778/4885IDO1 3089/4885 |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
| US-20180127476-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
| US-10968264-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | LMNA 3968/4885SMN1; SMN2 4471/4885IDO1 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.